Description Module

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Description Module

The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.

Description Module path is as follows:

Study -> Protocol Section -> Description Module

Description Module

Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2025-12-25 @ 3:29 AM
NCT ID: NCT01685905
Brief Summary: The purposes of this study 1. to compare the positivity of tuberculin skin test(TST) and QuantiFERON-TB Gold (QFT-G), and determine the level of agreement between two tests in patients with rheumatic diseases 2. to evaluate the difference in the occurrence of active TB in patients who receive both QFT-G and TST compared with those who receive only TST for detecting of Latent tuberculosis infection(LTBI) who are candidates of TNF inhibitors.
Detailed Description: Study Assessment 1. The positive rates of QFT-G and TST as a screening test for LTBI * The positive rates of QFT-G and TST will be analyzed * Additional analysis will be performed according to the type of disease 2. The agreement between QFT-G and TST as a screening test for LTBI * The agreement between QFT-G and TST will be analyzed for patients with rheumatic diseases who examined both QFT-G and TST * Additional analysis will be performed according to the type of disease 3. The correlation of the occurrence of active TB and two tests (QFT-G and TST) * The analysis of the correlation of the occurrence of active TB and two tests will be conducted for patients who have experienced anti-TNF agents 3-1. The occurrence of active TB in accordance with results of TST 3-2. The occurrence of active TB in accordance with results of QFT-G 3-3. The difference in the occurrence of active TB in patients performed both QFT-G and TST compared with those performed only TST for detecting of LTBI who are candidates of TNF inhibitors (pilot study).
Study: NCT01685905
Study Brief:
Protocol Section: NCT01685905